WO2005049053A1 - Composition comprenant un compose de magnesium et/ou un sel de magnesium ameliorant les dysfonctionnements sexuels - Google Patents
Composition comprenant un compose de magnesium et/ou un sel de magnesium ameliorant les dysfonctionnements sexuels Download PDFInfo
- Publication number
- WO2005049053A1 WO2005049053A1 PCT/KR2004/003016 KR2004003016W WO2005049053A1 WO 2005049053 A1 WO2005049053 A1 WO 2005049053A1 KR 2004003016 W KR2004003016 W KR 2004003016W WO 2005049053 A1 WO2005049053 A1 WO 2005049053A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- magnesium
- composition
- sexual dysfunction
- ginseng
- improving sexual
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 65
- 201000001880 Sexual dysfunction Diseases 0.000 title claims abstract description 23
- 231100000872 sexual dysfunction Toxicity 0.000 title claims abstract description 22
- 150000002681 magnesium compounds Chemical class 0.000 title claims abstract description 12
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 title claims description 11
- 239000011777 magnesium Substances 0.000 title claims description 11
- 229910052749 magnesium Inorganic materials 0.000 title claims description 11
- 239000000284 extract Substances 0.000 claims abstract description 43
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims abstract description 38
- 229930064664 L-arginine Natural products 0.000 claims abstract description 38
- 235000014852 L-arginine Nutrition 0.000 claims abstract description 38
- 159000000003 magnesium salts Chemical class 0.000 claims abstract description 13
- 239000004615 ingredient Substances 0.000 claims abstract description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 28
- 239000001755 magnesium gluconate Substances 0.000 claims description 25
- 229960003035 magnesium gluconate Drugs 0.000 claims description 25
- 235000015778 magnesium gluconate Nutrition 0.000 claims description 25
- IAKLPCRFBAZVRW-XRDLMGPZSA-L magnesium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;hydrate Chemical compound O.[Mg+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O IAKLPCRFBAZVRW-XRDLMGPZSA-L 0.000 claims description 25
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 18
- 229940091250 magnesium supplement Drugs 0.000 claims description 10
- 235000019359 magnesium stearate Nutrition 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 239000000395 magnesium oxide Substances 0.000 claims description 7
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 7
- 229960000869 magnesium oxide Drugs 0.000 claims description 7
- 235000012245 magnesium oxide Nutrition 0.000 claims description 7
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims description 7
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 4
- 241000208340 Araliaceae Species 0.000 claims description 3
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 3
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 235000013305 food Nutrition 0.000 claims description 3
- 235000008434 ginseng Nutrition 0.000 claims description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 3
- 239000004337 magnesium citrate Substances 0.000 claims description 3
- 229960005336 magnesium citrate Drugs 0.000 claims description 3
- 235000002538 magnesium citrate Nutrition 0.000 claims description 3
- OVGXLJDWSLQDRT-UHFFFAOYSA-L magnesium lactate Chemical compound [Mg+2].CC(O)C([O-])=O.CC(O)C([O-])=O OVGXLJDWSLQDRT-UHFFFAOYSA-L 0.000 claims description 3
- 239000000626 magnesium lactate Substances 0.000 claims description 3
- 235000015229 magnesium lactate Nutrition 0.000 claims description 3
- 229960004658 magnesium lactate Drugs 0.000 claims description 3
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 2
- 229960002337 magnesium chloride Drugs 0.000 claims description 2
- 235000011147 magnesium chloride Nutrition 0.000 claims description 2
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 claims description 2
- 239000000347 magnesium hydroxide Substances 0.000 claims description 2
- 229910001862 magnesium hydroxide Inorganic materials 0.000 claims description 2
- 229940057948 magnesium stearate Drugs 0.000 claims description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 2
- 229960003390 magnesium sulfate Drugs 0.000 claims description 2
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 2
- 239000012046 mixed solvent Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 21
- 231100000957 no side effect Toxicity 0.000 abstract description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 28
- 210000005226 corpus cavernosum Anatomy 0.000 description 22
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 238000009472 formulation Methods 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 210000003029 clitoris Anatomy 0.000 description 10
- 230000004044 response Effects 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 210000003899 penis Anatomy 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 229920002472 Starch Polymers 0.000 description 8
- 239000008107 starch Substances 0.000 description 8
- 235000019698 starch Nutrition 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 7
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 7
- 229960001802 phenylephrine Drugs 0.000 description 7
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 6
- 229960004373 acetylcholine Drugs 0.000 description 6
- ZOOGRGPOEVQQDX-UHFFFAOYSA-N cyclic GMP Natural products O1C2COP(O)(=O)OC2C(O)C1N1C=NC2=C1NC(N)=NC2=O ZOOGRGPOEVQQDX-UHFFFAOYSA-N 0.000 description 6
- 239000008213 purified water Substances 0.000 description 6
- KCWZGJVSDFYRIX-YFKPBYRVSA-N N(gamma)-nitro-L-arginine methyl ester Chemical compound COC(=O)[C@@H](N)CCCN=C(N)N[N+]([O-])=O KCWZGJVSDFYRIX-YFKPBYRVSA-N 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 230000008602 contraction Effects 0.000 description 5
- 201000001881 impotence Diseases 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 230000001568 sexual effect Effects 0.000 description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 4
- 208000010228 Erectile Dysfunction Diseases 0.000 description 4
- 241000402754 Erythranthe moschata Species 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 239000002131 composite material Substances 0.000 description 4
- 230000004064 dysfunction Effects 0.000 description 4
- 210000003038 endothelium Anatomy 0.000 description 4
- XJNUECKWDBNFJV-UHFFFAOYSA-N hexadecyl 2-ethylhexanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)C(CC)CCCC XJNUECKWDBNFJV-UHFFFAOYSA-N 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 4
- 210000002460 smooth muscle Anatomy 0.000 description 4
- 230000004913 activation Effects 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 3
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 3
- 230000004648 relaxation of smooth muscle Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 2
- 208000008167 Magnesium Deficiency Diseases 0.000 description 2
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 2
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 102000007637 Soluble Guanylyl Cyclase Human genes 0.000 description 2
- 108010007205 Soluble Guanylyl Cyclase Proteins 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 102000011016 Type 5 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 description 2
- 108010037581 Type 5 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 2
- 102000055135 Vasoactive Intestinal Peptide Human genes 0.000 description 2
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 229940008099 dimethicone Drugs 0.000 description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000001856 erectile effect Effects 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 2
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 235000004764 magnesium deficiency Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 230000018052 penile erection Effects 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000036299 sexual function Effects 0.000 description 2
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 description 1
- RQFCJASXJCIDSX-UHFFFAOYSA-N 14C-Guanosin-5'-monophosphat Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(COP(O)(O)=O)C(O)C1O RQFCJASXJCIDSX-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 108060003345 Adrenergic Receptor Proteins 0.000 description 1
- 102000017910 Adrenergic receptor Human genes 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 102100038518 Calcitonin Human genes 0.000 description 1
- 102000004414 Calcitonin Gene-Related Peptide Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000004654 Cyclic GMP-Dependent Protein Kinases Human genes 0.000 description 1
- 108010003591 Cyclic GMP-Dependent Protein Kinases Proteins 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 241000208688 Eucommia Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 241001106041 Lycium Species 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 206010034310 Penile pain Diseases 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960000711 alprostadil Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 230000037007 arousal Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 229940086555 cyclomethicone Drugs 0.000 description 1
- 229940049657 cyclomethicone 5 Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 235000008524 evening primrose extract Nutrition 0.000 description 1
- 229940089020 evening primrose oil Drugs 0.000 description 1
- 239000010475 evening primrose oil Substances 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000013022 formulation composition Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 1
- 230000001435 haemodynamic effect Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000030214 innervation Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 230000001129 nonadrenergic effect Effects 0.000 description 1
- 230000002536 noncholinergic effect Effects 0.000 description 1
- 230000002474 noradrenergic effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000003049 pelvic bone Anatomy 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 201000011264 priapism Diseases 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 230000009329 sexual behaviour Effects 0.000 description 1
- 229960003310 sildenafil Drugs 0.000 description 1
- 229960002639 sildenafil citrate Drugs 0.000 description 1
- DEIYFTQMQPDXOT-UHFFFAOYSA-N sildenafil citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 DEIYFTQMQPDXOT-UHFFFAOYSA-N 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- AWLILQARPMWUHA-UHFFFAOYSA-M thiopental sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC([S-])=NC1=O AWLILQARPMWUHA-UHFFFAOYSA-M 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 239000002550 vasoactive agent Substances 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 230000000982 vasogenic effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- YEFOAORQXAOVJQ-UHFFFAOYSA-N wuweizischun A Natural products C1C(C)C(C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
Definitions
- Composition comprising a magnesium compound and/or a magnesium salt for improving sexual dysfunction
- the present invention relates to the composition for improving sexual
- magnesium compounds and magnesium salts are magnesium compounds and magnesium salts.
- the erection in males or females is an essential process during
- Penile and clitoral erections are the haemodynamic event which is dependent
- Erectile Dysfunction may be
- NANC non-adrenergic, non-cholinergic
- nitric oxide such as calcitonin gene related peptide
- CGRP vasoactive intestinal peptide
- VIP vasoactive intestinal peptide
- NO which is synthesized from L-arginine by nitric
- sGC soluble guanylate cyclase
- cGMP guanosine 3',5'-monophosphate
- PDE5 phosphodiesterase 5
- prostaglandin based compounds i.e. alprostadil which can be
- compositions comprising a mixture of two or more ingredients selected
- dysfunction comprising one or more ingredients selected from the group consisting of magnesium compounds and magnesium salts.
- composition may further comprise L-arginine or ginseng-alcohol extract,
- composition in accordance with the present invention may comprise one
- ingredients selected from the group consisting of magnesium compounds and
- magnesium salts in an amount of preferably 1 to 80% by weight, and more preferably 5
- L-arginine or ginseng-alcohol extract further comprises L-arginine or ginseng-alcohol extract, or L-arginine and ginseng-
- arginine is 1 to 80% by weight based on the total weight of the composition
- content of the gmseng-alcohol extract is 1 to 80% by weight based on the total weight
- the content of L-arginine is 5 to 50% by weight
- extract is 2 to 50% by weight based on the total weight of the composition.
- composition in accordance with the present invention may be any composition in accordance with the present invention.
- Magnesium one of electrolytes essential for all the cells of body, maintains
- the present inventors have found that magnesium facilitates production and liberation of nitric oxide (NO) in penile corpus cavernosum and clitoral cavernosum, and applied this finding to the present invention. Therefore, the composition in accordance with the present invention has an effect on improving sexual dysfunction by promoting production and liberation of nitric oxide (NO) in penile corpus cavernosum and clitoral cavernosum, resulting in relaxation of smooth muscles thus leading to increased blood flow to the penis and clitoris.
- NO nitric oxide
- present invention are magnesium oxide, magnesium hydroxide and the like.
- representative examples of magnesium salts in according to the present invention are magnesium chloride, magnesium sulfate, magnesium gluconate, magnesium citrate, magnesium lactate, magnesium stearate and the like.
- magnesium gluconate, magnesium citrate, magnesium lactate and magnesium oxide are more preferable.
- the compositions in accordance with the present invention comprising not only magnesium compounds and/or magnesium salts, but also a ginseng-alcohol extract containing L-arginine (used as a substrate of NO) and gmsenosides which are
- invention is that it may improve peripheral blood circulation leading to fundamental
- composition contains a magnesium salt which is known to
- cardiovascular diseases including diabetes mellitus and hypertension, and senescence which are fundamental causes of sexual dysfunction.
- present invention is obtained by placing dried ginseng in 1 to 10-fold weight of
- composition for improving sexual dysfunction in accordance with the
- present invention may be formulated in various forms that contain pharmaceutically
- oral formulations such as tablets, capsules and
- transdermal preparations may include creams, gels,
- composition in accordance with the present invention may be used in
- composition of the present invention may be any one of various food products.
- the composition of the present invention may be any one of various food products.
- the composition of the present invention may be any one of various food products.
- the composition of the present invention may be any one of various food products.
- the composition of the present invention may be any one of various food products.
- the composition of the present invention may be any one of various food products.
- the composition of the present invention may be any one of the present invention.
- Fig. 1 is a graph showing concentration-dependent effects of L-arginine
- Fig. 2 is a graph showing concentration-dependent effects of L-arginine
- Fig. 3 is a bar graph showing the comparison of the relaxation effects on penile
- Fig. 4 is a bar graph showing the inhibition effects of L-NAME (10 " M, an
- Magnesium gluconate was mixed with lactose, starch and pre-gelatinized corn
- Magnesium gluconate was mixed with starch and magnesium stearate, and the
- Glycerol monostearate 2 Polyoxyethylene sorbitan .
- Dimethicone, cyclomethicone, cetylethyl hexanoate, cetanol, stearic acid, glycerol monostearate, polyoxyethylene sorbitan monostearate and methyl paraben were dissolved by increasing the temperature to 75°C.
- step (1) was poured into the solution of step (2) and
- Carbopol was dissolved in purified water.
- step (3) To the solution of step (2) was added Sepigel 305, and then mixed and stirred.
- tissues for experiments were prepared from New Zealand White rabbits, weighing 2.5 to 3.0 kg. Each rabbit was anesthetized by
- rabbit clitoral cavernosum tissue were vertically placed in 5ml of the organ bath and the
- the temperature of the organ bath was maintained at 37°C.
- PhE phenylephrine
- each of L-arginine (0.1, 0.3, 0.6 and 1 g/L),
- ginseng-alcohol extract (0.01, 0.03, 0.1, 0.3 and 1 g/L), and magnesium gluconate
- each of L-arginine (0.1, 0.3, 0.6 and 1 g/L), ginseng-
- composite composition are brought about through action on the NO system.
- the present invention provides a composition for improving
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
L'invention porte sur une composition améliorant les dysfonctionnements sexuels comprenant un ou plusieurs ingrédients choisi parmi des composés de magnésium et/ou des sels de magnésium de la L-arginine ou de l'extrait alcoolique de ginseng ou de la L-arginine et de l'extrait alcoolique de ginseng. Ladite composition, d'une utilisation commode et qui donne a d'excellents résultats sans effets secondaires, est fondamentalement capable de prévenir et traiter les dysfonctionnements sexuels.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020030082690A KR20050048940A (ko) | 2003-11-20 | 2003-11-20 | 마그네슘화합물 및/또는 마그네슘염을 포함하는 성기능장애 개선용 조성물 |
| KR10-2003-0082690 | 2003-11-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2005049053A1 true WO2005049053A1 (fr) | 2005-06-02 |
Family
ID=34617263
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/KR2004/003016 WO2005049053A1 (fr) | 2003-11-20 | 2004-11-19 | Composition comprenant un compose de magnesium et/ou un sel de magnesium ameliorant les dysfonctionnements sexuels |
Country Status (2)
| Country | Link |
|---|---|
| KR (1) | KR20050048940A (fr) |
| WO (1) | WO2005049053A1 (fr) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2931361A1 (fr) * | 2008-05-20 | 2009-11-27 | Menvielle Bourg Fabienne Joanny | Systeme a base de magnesium et son utilisation en cosmetique |
| EP2139466A2 (fr) * | 2007-03-22 | 2010-01-06 | Guosong Liu | Compositions contenant du magnésium et leur utilisation |
| WO2010061395A1 (fr) | 2008-11-30 | 2010-06-03 | Benzion Geshuri | Formulation à base de l-arginine s'administrant par voie orale |
| WO2011055917A2 (fr) * | 2009-11-03 | 2011-05-12 | 한남대학교 산학협력단 | Dérivés d'arginine ou sels de ceux-ci présentant les effets d'amélioration de la fonction sexuelle, composition améliorant la fonction sexuelle les comprenant, et procédé de préparation associé |
| US8142803B2 (en) | 2007-03-22 | 2012-03-27 | Magceutics, Inc. | Magnesium compositions and uses thereof for neurological disorders |
| US8377473B2 (en) | 2009-07-01 | 2013-02-19 | Magceutics, Inc. | Slow release magnesium composition and uses thereof |
| US8399017B2 (en) | 2008-05-20 | 2013-03-19 | Fabienne Joanny | Use of a matrix for orally administering sustained release magnesium, and composition containing said matrix |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5523087A (en) * | 1995-02-15 | 1996-06-04 | Bio-Virus Research Incorporated | Pharmaceutical compositions for the treatment of diabetic male sexual dysfunction |
| US6007824A (en) * | 1998-07-09 | 1999-12-28 | Duckett; Melvin J. | Natural composition and method for the treatment of sexual dysfunction |
| KR20010009653A (ko) * | 1999-07-12 | 2001-02-05 | 유제경 | 성기능 장애를 위한 치료용 조성물 |
| US6548087B1 (en) * | 1999-07-12 | 2003-04-15 | Frances B. Kent | Nutritional supplement |
-
2003
- 2003-11-20 KR KR1020030082690A patent/KR20050048940A/ko not_active Application Discontinuation
-
2004
- 2004-11-19 WO PCT/KR2004/003016 patent/WO2005049053A1/fr active Application Filing
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5523087A (en) * | 1995-02-15 | 1996-06-04 | Bio-Virus Research Incorporated | Pharmaceutical compositions for the treatment of diabetic male sexual dysfunction |
| US6007824A (en) * | 1998-07-09 | 1999-12-28 | Duckett; Melvin J. | Natural composition and method for the treatment of sexual dysfunction |
| KR20010009653A (ko) * | 1999-07-12 | 2001-02-05 | 유제경 | 성기능 장애를 위한 치료용 조성물 |
| US6548087B1 (en) * | 1999-07-12 | 2003-04-15 | Frances B. Kent | Nutritional supplement |
Non-Patent Citations (1)
| Title |
|---|
| OMU ET AL: "Magnesium inhuman semen:possible role in premature ejaculation", ARCH ANDROL., vol. 46, no. 1, 2001, pages 59 - 66 * |
Cited By (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9616038B2 (en) | 2007-03-22 | 2017-04-11 | Neurocentria, Inc. | Magnesium compositions and uses thereof for neurological disorders |
| AU2008227465B2 (en) * | 2007-03-22 | 2014-02-06 | Magceutics, Inc. | Magnesium compositions and uses thereof |
| EP2139466A2 (fr) * | 2007-03-22 | 2010-01-06 | Guosong Liu | Compositions contenant du magnésium et leur utilisation |
| US9737563B2 (en) | 2007-03-22 | 2017-08-22 | Neurocentria, Inc. | Magnesium compositions and uses thereof for neurological disorders |
| JP2010522216A (ja) * | 2007-03-22 | 2010-07-01 | リュー，グオソン | マグネシウム組成物およびその使用 |
| EP2139466A4 (fr) * | 2007-03-22 | 2010-12-22 | Magceutics Inc | Compositions contenant du magnésium et leur utilisation |
| US9757414B2 (en) | 2007-03-22 | 2017-09-12 | Neurocentria, Inc. | Magnesium compositions and uses thereof for neurological disorders |
| US9125878B2 (en) | 2007-03-22 | 2015-09-08 | Magceutics, Inc. | Magnesium compositions and uses thereof for neurological disorders |
| JP2013155197A (ja) * | 2007-03-22 | 2013-08-15 | Guosong Liu | マグネシウム組成物およびその使用 |
| US8142803B2 (en) | 2007-03-22 | 2012-03-27 | Magceutics, Inc. | Magnesium compositions and uses thereof for neurological disorders |
| US8163301B2 (en) | 2007-03-22 | 2012-04-24 | Magceutics, Inc. | Magnesium compositions and uses thereof for metabolic disorders |
| US8178133B2 (en) | 2007-03-22 | 2012-05-15 | Magceutics, Inc. | Magnesium compositions and uses thereof |
| US8178132B2 (en) | 2007-03-22 | 2012-05-15 | Magceutics, Inc. | Magnesium-containing food compositions |
| US8178118B2 (en) | 2007-03-22 | 2012-05-15 | Magceutics, Inc. | Magnesium compositions and uses thereof for cognitive function |
| US8637061B2 (en) | 2007-03-22 | 2014-01-28 | Magceutics, Inc. | Magnesium compositions and uses thereof for neurological disorders |
| US8529950B2 (en) | 2008-05-20 | 2013-09-10 | Fabienne Joanny | Magnesium system and use thereof in the cosmetics industry |
| US8399017B2 (en) | 2008-05-20 | 2013-03-19 | Fabienne Joanny | Use of a matrix for orally administering sustained release magnesium, and composition containing said matrix |
| FR2931361A1 (fr) * | 2008-05-20 | 2009-11-27 | Menvielle Bourg Fabienne Joanny | Systeme a base de magnesium et son utilisation en cosmetique |
| WO2009150324A1 (fr) * | 2008-05-20 | 2009-12-17 | Fabienne Joanny | Systeme a base de magnesium et son utilisation en cosmetique |
| EP2369925A4 (fr) * | 2008-11-30 | 2012-06-13 | Benzion Geshuri | Formulation à base de l-arginine s'administrant par voie orale |
| EP2369925A1 (fr) * | 2008-11-30 | 2011-10-05 | Benzion Geshuri | Formulation à base de l-arginine s'administrant par voie orale |
| WO2010061395A1 (fr) | 2008-11-30 | 2010-06-03 | Benzion Geshuri | Formulation à base de l-arginine s'administrant par voie orale |
| US8377473B2 (en) | 2009-07-01 | 2013-02-19 | Magceutics, Inc. | Slow release magnesium composition and uses thereof |
| US8734855B2 (en) | 2009-07-01 | 2014-05-27 | Magceutics, Inc. | Slow release magnesium composition and uses thereof |
| WO2011055917A3 (fr) * | 2009-11-03 | 2011-11-03 | 한남대학교 산학협력단 | Dérivés d'arginine ou sels de ceux-ci présentant les effets d'amélioration de la fonction sexuelle, composition améliorant la fonction sexuelle les comprenant, et procédé de préparation associé |
| WO2011055917A2 (fr) * | 2009-11-03 | 2011-05-12 | 한남대학교 산학협력단 | Dérivés d'arginine ou sels de ceux-ci présentant les effets d'amélioration de la fonction sexuelle, composition améliorant la fonction sexuelle les comprenant, et procédé de préparation associé |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20050048940A (ko) | 2005-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0714300B1 (fr) | Methode de modulation de la reponse sexuelle chez l'homme | |
| KR102093872B1 (ko) | 지방제거용 주사제 조성물 및 이의 제조방법 | |
| TWI280136B (en) | Composition containing dipeptide of histidine and alanine for reducing uric acid | |
| CN101460159B (zh) | 疲劳缓解剂 | |
| WO2008031322A1 (fr) | Application d'un médicament inhibiteur d'acétylcholine estérase à base d'un extrait de leonurus utilisé en tant que cholinomimétique | |
| AU2018255294A1 (en) | Parenteral non-systemic administration of buffering agents for inhibiting metastasis of solid tumors, hyperpigmentation and gout | |
| WO2012000377A1 (fr) | Composition pharmaceutique contenant de la lévocarnitine et du dobésilate | |
| EP1658854A2 (fr) | Formulations utiles pour le traitement d'impuissance mâle et féminine | |
| CN111840508A (zh) | 一种预防及治疗男性性功能障碍的外用制剂及其应用 | |
| JP2003534286A (ja) | 勃起障害症状改善のために、刺激物質の活性成分としてプロアントシアニジン、一酸化窒素源としてｌアルギニン又はその塩の使用 | |
| BRPI0614434A2 (pt) | composições compreendendo um doador de no e um ditiolano e o uso das mesmas para o melhoramento da função sexual | |
| WO2005049053A1 (fr) | Composition comprenant un compose de magnesium et/ou un sel de magnesium ameliorant les dysfonctionnements sexuels | |
| US20200384051A1 (en) | Herbal formulations of carnivorous plants and methods for treating inflammation | |
| RU2099078C1 (ru) | Средство, обладающее антистрессовым, стресспротекторным, ноотропным, антиалкогольным и антинаркотическим действием, способы профилактики и лечения с его использованием | |
| JP5602696B2 (ja) | プロアントシアニジンによる性的機能及び性器血管系の改善 | |
| KR20190117318A (ko) | 우수한 안정성을 갖는 데옥시콜린산 함유 주사제 조성물 및 이의 제조방법 | |
| CN114469971A (zh) | 白头翁皂苷b5在制备治疗阳痿药物中的应用 | |
| CN110327321B (zh) | 对饮酒导致中枢神经突触可塑性改变具有解救作用氨基酸在制备治疗酒精成瘾的药物中的应用 | |
| RU2240131C1 (ru) | Средство "артровит" для профилактики и лечения артритов и артрозов | |
| US11344505B1 (en) | Herbal formulations of carnivorous plants and methods for treating inflammation | |
| JP2002527472A (ja) | 消化不良の処置 | |
| US6340474B1 (en) | Composition for potentiating a growth hormone and a method for preparation of said composition | |
| KR100301263B1 (ko) | 피부외용 남성 성기능장애 치료제 및 그의 제조방법 | |
| US6916845B2 (en) | Method for prevention and treatment of male and female sexual dysfunction | |
| KR20120102214A (ko) | 한방복합 생약 소염 진통 외용제 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
| 122 | Ep: pct application non-entry in european phase |